BioWorld Asia

April 24, 2002

Xenova Enters Potential $63M Deal With Genentech For OX40

LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International) Read More

Finnish Companies Biotie, Contral, Carbion Plan Three-Way Merger

Leukemia Case Report Gives Gene Therapy Projects Pause For Thought

Apovia Raises EUR19M Privately To Fund Vaccine Development

YM BioSciences Plans Floats On AIM, TSE To Raise Up To C$40M

Faust Pharmaceuticals Obtains $2.6M To Develop CNS Drugs

Report Says EU Biotech Trails U.S. Due To Lack Of Coordination

Molecular Skincare Spun Out To Develop Skin Disease Treatments

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...